Table 4.
Lipid Profile and Glucose Assessment at Baseline and 8 Weeks in Placebo and the Herbal Blend Groups
| |
|
Baseline |
Week 8 |
||||
|---|---|---|---|---|---|---|---|
| Metabolic marker (units) | Normal range | Placebo (n=46) | Herbal blend (n=49) | P value | Placebo (n=46) | Herbal blend (n=49) | P value |
| Cholesterol (mg/dL) | <200 | 198.9±6.2 | 204.9±5.4 | .4524 | 187.4±5.1 | 176.6±4.4 | .0024* |
| Triglycerides (mg/dL) | 10–150 | 157.9±7.5 | 163.7±7.0 | .5257 | 117.1±7.5 | 95.6±3.9 | <.0001* |
| LDL (mg/dL) | <130 | 140.6±1.4 | 142.6±1.7 | .3921 | 139.9±1.3 | 136.9±2.4 | .1162 |
| HDL (mg/dL) | >40–60 | 34.7±0.8 | 34.6±0.8 | .9073 | 35.6±0.8 | 37.2±0.8 | .1139 |
| LHR | NA | 4.1±0.1 | 4.2±0.1 | .5786 | 4.0±0.1 | 3.8±0.1 | .0606 |
| Fasting glucose (mg/dL) | <100 | 107.7±1.7 | 109.3±2.6 | .7400 | 100.7±1.3 | 95.9±1.5 | .0100* |
Results are presented as mean±SEM. Normal ranges were obtained from Medline.14
*Significant difference between placebo and the herbal groups.
LDL, low-density lipoproteins; HDL, high-density lipoproteins; LHR, LDL/HDL ratio.